“Covaxin has undergone all necessary clinical trials and the Phase 3 Efficacy Trials revealed a 77.8 percent vaccine against symptomatic Covid-19 disease, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.”
The company added that the efficacy against severe symptomatic Covid-19 disease is shown to be 93.4 percent and the efficacy data demonstrates 63.6 percent protection against asymptomatic COVID-19.
The company’s response came on a petition filed by Jacob Puliyel, a former member of the National Technical Advisory Group on Immunization, seeking the data of clinical trials and adverse effects of Covid vaccines and also challenging the vaccine mandates issued by some state governments.
The company said the petitioner has made baseless allegations against the approval granted to it, when the same was carried after strict adherence to protocols established by the regulatory authorities after conducting due diligence, and urged the top court to dismiss the PIL.
“The petitioner has falsely and without correct reference to the key documents, alleged that the respondent company has not published its clinical trial data. The rules and practice are fairly clear in this aspect from a reading of the WHO Statement on public disclosure of clinical trial results,” it added.
It also said submission of the petitioner that it has not published Phase 3 clinical trial data in peer reviewed journals is unsubstantiated as it has submitted the key outcomes and main findings in one of the most respected and peer reviewed journal in the field of medicine, The Lancet.
“It is also submitted that not only is the endeavor of the petitioner, defamatory to the answering respondent, the unsubstantiated pleas therein are likely to cause hysteria and panic during the present global pandemic and promote vaccine hesitancy. On that ground alone, the present writ petition is liable to be dismissed,” said the document.
The company said it is a matter of pride for this nation that a domestically manufactured vaccine has come as a solace for not only India but for the world in these trying times.
It also accused the petitioner of being not a bona fide litigant as he had earlier filed a plea seeking segregated data of ‘Rotovac vaccine’ made by it in Delhi High Court. In 2015, this plea was by the dismissed by the high court and the top court in 2016 and he did not disclose this in instant PIL.
The top court has reserved its judgment in the matter.
Source: IANS
